ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2219

Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)

Ikuko Tanaka1, Mari Ushikubo 2, Misako Konishi 2, Yutaro Hayashi 2, Satoshi Hama 3, Keisuke Izumi 2, Yutaka Okano 2, Shigenori Tamaki 4 and Hisaji Ohshima 2, 1Nagoya Rheumatology Clinic, Ngoya, Japan, 2National Tokyo Medical Center, Tokyo, Japan, 3tokyo medical center, tokyo, Japan, 4Nagoya Rheumatology Clinic, Nagoya, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , , ,

Session Information

Date: Tuesday, November 12, 2019

Title: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to compare the therapeutic efficacy to GIO between bisphosphonate and denosumab on the basis of randomized control study (GIBID Study, UMIN000014341).

Methods: The inclusion criteria were as follows, glucocorticoids on, bone mineral density (BMD) < 80% in %YAM at the lumbar spine/femoral neck or fragile fracture at the spine, ≥1 year without bisphoshonates, ≥18 years old. The BMD was measured at the lumbar spine and femoral neck with GE Lunar iDXA. Incident fractures were evaluated with the semiquantative method (Genant) at the thoracic and lumbar spine. Medications, risedronate (17.5mg/W or 75mg/M, group B) or denosmab (60mg/6M, group P), were randomly assigned to the patients. The primary outcome was the changes in lumbar BMD (l-BMD) at 2 years.

Results: The included individuals were 28 rheumatoid arthritis (RA), 22 systemic lupus erythematosus (SLE), 17 polymyalgia rheumatic (PMR), other connective tissue diseases (CTDs) in total 89. The demographics of the group B and the group P were as follow, the number: 48/41 (B/P); female: 42/31; Age (mean): 66.0/70.6; prednisolone: 6.1/7.3mg/day; l-BMD; 0.959/0.928g/cm2; prevalent deformity at spine: 52/49%. No significant differences was observed between the groups. The change at 2 years in lBMD in group P (0.063+/-0.069 (mean+/-SD)) was significantly higher than that in group B (0.017+/-0.043) (p< 0.001). The numbers (rates) of incident fracture at 2 year were 6 (15%) in group B and 0 (0%) in group P (p< 0.01). Any serious adverse events due to the study drugs were not seen in the both groups.

Conclusion: These results suggest that denosmab is effective and safe for treatment of glucocorticoid-induced osteoporosis.

Disclosure: I. Tanaka, None; M. Ushikubo, None; M. Konishi, None; Y. Hayashi, None; S. Hama, None; K. Izumi, None; Y. Okano, None; S. Tamaki, None; H. Ohshima, None.

To cite this abstract in AMA style:

Tanaka I, Ushikubo M, Konishi M, Hayashi Y, Hama S, Izumi K, Okano Y, Tamaki S, Ohshima H. Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/randomized-control-study-in-glucocorticoid-induced-osteoporosis-treated-with-bisphosphonate-or-denosumab-gobid/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/randomized-control-study-in-glucocorticoid-induced-osteoporosis-treated-with-bisphosphonate-or-denosumab-gobid/